Literature DB >> 28938428

GLP-1 Receptor Activation Inhibits Palmitate-Induced Apoptosis via Ceramide in Human Cardiac Progenitor Cells.

Anna Leonardini1, Rossella D'Oria1, Maria Angela Incalza1, Cristina Caccioppoli1, Valentina Andrulli Buccheri1, Angelo Cignarelli1, Domenico Paparella2,3, Vito Margari3, Annalisa Natalicchio1, Sebastio Perrini1, Francesco Giorgino1, Luigi Laviola1.   

Abstract

Context: Increased apoptosis of cardiomyocytes and cardiac progenitor cells (CPCs) in response to saturated fatty acids (SFAs) can lead to myocardial damage and dysfunction. Ceramides mediate lipotoxicity-induced apoptosis. Glucagonlike peptide-1 receptor (GLP1R) agonists exert beneficial effects on cardiac cells in experimental models. Objective: To investigate the protective effects of GLP1R activation on SFA-mediated apoptotic death of human CPCs. Design: Human CPCs were isolated from cardiac appendages of nondiabetic donors and then exposed to palmitate with or without pretreatment with the GLP1R agonist exendin-4. Ceramide accumulation was evaluated by immunofluorescence. Expression of key enzymes in de novo ceramide biosynthesis was studied by quantitative reverse-transcription polymerase chain reaction and immunoblotting. Apoptosis was evaluated by measuring release of oligonucleosomes, caspase-3 cleavage, caspase activity, and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling.
Results: Exposure of the CPCs to palmitate resulted in 2.3- and 1.9-fold higher expression of ceramide synthase 5 (CERS5) and ceramide desaturase-1, respectively (P < 0.05). This was associated with intracellular accumulation of ceramide and activation of c-Jun NH2-terminal protein kinase (JNK) signaling and apoptosis (P < 0.05). Both coincubation with fumonisin B1, a specific ceramide synthase inhibitor, and CERS5 knockdown prevented ceramide accumulation, JNK activation, and apoptosis in response to palmitate (P < 0.05). Exendin-4 also prevented the activation of the ceramide biosynthesis and JNK in response to palmitate, inhibiting apoptosis (P < 0.05). Conclusions: Excess palmitate results in activation of ceramide biosynthesis, JNK signaling, and apoptosis in human CPCs. GLP1R activation counteracts this lipotoxic damage via inhibition of ceramide generation, and this may represent a cardioprotective mechanism.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28938428     DOI: 10.1210/jc.2017-00970

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Authors:  Mauro Cataldi; Angelo Cignarelli; Francesco Giallauria; Giovanna Muscogiuri; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2020-07-20

2.  Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate-induced apoptosis.

Authors:  Seher Balaban; Lisa S Lee; Bianca Varney; Atqiya Aishah; Quanqing Gao; Robert F Shearer; Darren N Saunders; Thomas Grewal; Andrew J Hoy
Journal:  Mol Oncol       Date:  2018-08-29       Impact factor: 6.603

Review 3.  The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor.

Authors:  Rossella D'Oria; Rossella Schipani; Anna Leonardini; Annalisa Natalicchio; Sebastio Perrini; Angelo Cignarelli; Luigi Laviola; Francesco Giorgino
Journal:  Oxid Med Cell Longev       Date:  2020-05-14       Impact factor: 6.543

4.  Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.

Authors:  Maurice B Bizino; Ingrid M Jazet; Paul de Heer; Huub J van Eyk; Ilona A Dekkers; Patrick C N Rensen; Elisabeth H M Paiman; Hildebrandus J Lamb; Johannes W Smit
Journal:  Diabetologia       Date:  2019-11-05       Impact factor: 10.122

5.  Evaluation of the In Vitro Damage Caused by Lipid Factors on Stem Cells from a Female Rat Model of Type 2 Diabetes/Obesity and Stress Urinary Incontinence.

Authors:  Istvan Kovanecz; Robert Gelfand; Sheila Sharifzad; Alec Ohanian; William Brent DeCastro; Carley Cooper; Guiting Lin; Tom Lue; Nestor F Gonzalez-Cadavid
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

Review 6.  Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.

Authors:  Nicola Marrano; Giuseppina Biondi; Anna Borrelli; Angelo Cignarelli; Sebastio Perrini; Luigi Laviola; Francesco Giorgino; Annalisa Natalicchio
Journal:  Biomolecules       Date:  2021-02-15

7.  Vascular endothelial growth factor ameliorated palmitate-induced cardiomyocyte injury via JNK pathway.

Authors:  Shi-Ya Wang; Cao Zou; Xiao-Feng Liu; Yon-Jin Yan; Shun-Zhon Gu; Xun Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-11-17       Impact factor: 2.416

Review 8.  Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis.

Authors:  Angelo Cignarelli; Valentina Annamaria Genchi; Giulia Le Grazie; Irene Caruso; Nicola Marrano; Giuseppina Biondi; Rossella D'Oria; Gian Pio Sorice; Annalisa Natalicchio; Sebastio Perrini; Luigi Laviola; Francesco Giorgino
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-21       Impact factor: 5.555

Review 9.  Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far.

Authors:  Youssef M Shalaby; Anas Al Aidaros; Anjana Valappil; Bassam R Ali; Nadia Akawi
Journal:  Front Cell Dev Biol       Date:  2022-01-19

Review 10.  Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development.

Authors:  Victor García-González; José Fernando Díaz-Villanueva; Octavio Galindo-Hernández; Israel Martínez-Navarro; Gustavo Hurtado-Ureta; Abril Alicia Pérez-Arias
Journal:  Int J Mol Sci       Date:  2018-08-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.